MOTS-c

Exercise-Induced Expression

MOTS-c levels in skeletal muscle rise approximately 12-fold following exercise, with elevations persisting for several hours. Circulating MOTS-c also increases during and after physical activity. This positions MOTS-c as a molecular mediator of exercise's metabolic benefits — the signal that translates physical demand into cellular adaptation.²

Age-Related Decline

Endogenous MOTS-c expression declines with age alongside reduced physical capacity. Population genetic studies have identified a MOTS-c variant (m.1382A>C) associated with exceptional longevity in Japanese cohorts.²

Human Observational Studies

Multiple studies have examined circulating MOTS-c across metabolic and cardiovascular contexts:

• In obese adults, lower circulating MOTS-c independently correlated with reduced insulin sensitivity⁶⁵⁷⁸¹⁴

  Bone Metabolism

  Early research suggests MOTS-c influences bone remodeling. Preclinical data show effects on osteoblast and osteoclast activity, nudging the cells that build and break down bone toward a more balanced state. This extends the exercise-mimetic framing: MOTS-c appears to talk to bone as well as muscle and fat.³

  CB4211 Phase 1a/1b Trial

  CB4211, a MOTS-c analog, completed Phase 1a/1b clinical trials in 2021. Reductions in liver enzymes (ALT, AST) and trends toward weight loss were observed with acceptable tolerability. Development was discontinued due to formulation challenges rather than safety signals. This remains the only clinical trial of a MOTS-c analog to date.

Most mechanistic research comes from murine models. Human data is primarily observational, correlating endogenous MOTS-c levels with metabolic and cardiovascular phenotypes. The single clinical trial of a MOTS-c analog was discontinued before efficacy endpoints could be established. Cardiovascular, bone, and cardiac effects are preclinical only — human interventional data does not yet exist for these domains. Exercise-induction data in humans confirms the biological response but does not establish exogenous administration effects.

1. Lee C et al. "The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance." Cell Metab. 2015. PubMed
2. Reynolds JC et al. "MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis." Nat Commun. 2021. PubMed
3. Wan W et al. "Mitochondria-derived peptide MOTS-c: effects and mechanisms." J Transl Med. 2023. PubMed
4. Zhong L et al. "MOTS-c improves cardiac function and protects against pressure overload-induced cardiac dysfunction." J Cell Mol Med. 2022. PubMed
5. Du C et al. "Circulating MOTS-c levels are decreased in obese male children and adolescents and associated with insulin resistance." Pediatr Diabetes. 2018. PubMed
6. Cataldo LR et al. "Plasma MOTS-c levels are associated with insulin sensitivity in lean but not in obese individuals." J Investig Med. 2018. PubMed
7. Yilmaz H et al. "MOTS-c as CAD predictor." Eur Rev Med Pharmacol Sci. 2022. PubMed
8. Ramanjaneya M et al. "MOTS-c and coronary endothelial dysfunction." Int J Cardiol. 2018. PubMed
9. Mohtashami Z et al. "MOTS-c, the Most Recent Mitochondrial Derived Peptide in Human Aging and Age-Related Diseases." Int J Mol Sci. 2022. DOI
10. Lu H et al. "Mitochondrial-Encoded Peptide MOTS-c, Diabetes, and Aging-Related Diseases." Diabetes Metab J. 2023. DOI

For laboratory research use only.